Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Sebastien

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Journal of Pharmacokinetics and Pharmacodynamics|November 1, 2019
Cardiac risk assessment based on early Phase I data and PK-QTc analysis is concordant with the outcome of thorough QTc trials: an assessment based on eleven drug candidatesPuneet Gaitonde, Yeamin Huh, Borje Darpo, et al.
Epidemiology (Cambridge, Mass.)|May 31, 2023
An Overview of Current Methods for Real-world Applications to Generalize or Transport Clinical Trial Findings to Target Populations of InterestAlbee Y Ling, Maria E Montez-Rath, Paulo Carita, et al.
British Journal of Clinical Pharmacology|October 27, 2021
Joint modelling and simulation of M-protein dynamics and progression-free survival for alternative isatuximab dosing with pomalidomide/dexamethasoneHoai-Thu Thai, Nadia Gaudel, Marc Cerou, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 31, 2022
Exposure-response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myelomaFatiha Rachedi, Kimiko Koiwai, Nadia Gaudel-Dedieu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2024
Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5Javier Cortés, Sara A Hurvitz, Joyce O'Shaughnessy, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Journal of Pharmacokinetics and Pharmacodynamics|November 1, 2019
Cardiac risk assessment based on early Phase I data and PK-QTc analysis is concordant with the outcome of thorough QTc trials: an assessment based on eleven drug candidatesPuneet Gaitonde, Yeamin Huh, Borje Darpo, et al.
Epidemiology (Cambridge, Mass.)|May 31, 2023
An Overview of Current Methods for Real-world Applications to Generalize or Transport Clinical Trial Findings to Target Populations of InterestAlbee Y Ling, Maria E Montez-Rath, Paulo Carita, et al.
British Journal of Clinical Pharmacology|October 27, 2021
Joint modelling and simulation of M-protein dynamics and progression-free survival for alternative isatuximab dosing with pomalidomide/dexamethasoneHoai-Thu Thai, Nadia Gaudel, Marc Cerou, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 31, 2022
Exposure-response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myelomaFatiha Rachedi, Kimiko Koiwai, Nadia Gaudel-Dedieu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2024
Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5Javier Cortés, Sara A Hurvitz, Joyce O'Shaughnessy, et al.
Pageof 2